Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05452239 · ClinicalTrials.gov registry record · Phase 4
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
A Phase 4 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 608
- Enrollment target
NCT05452239: Completed Phase 4 study, sponsored by H. Lundbeck A/S.
NCT05452239 is a Phase 4 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 608 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05452239, a Phase 4 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 608 participants
- Enrollment target
Study Summary
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications. Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with headache, and acute medication use in adults who have migraine and MOH.
Primary Outcome
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * las
Interventions
- DRUG Placebo
- DRUG Eptinezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 608 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2025-03-13 |
| Phase | Phase 4 |
What the finished NCT05452239 record still lists
NCT05452239 is an interventional study that assigns participants to a tested intervention. The registered 608 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05452239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05452239 about?
NCT05452239 is a clinical study titled "A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache". Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications. Eptinezumab is a me...
What is the current status of trial NCT05452239?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 608 participants. The study started on 2022-07-01. Estimated completion is 2025-03-13.
What interventions are being tested in trial NCT05452239?
The interventions under investigation include: Placebo (DRUG), Eptinezumab (DRUG).
Who is sponsoring clinical trial NCT05452239?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05452239's enrollment target sits among peer trials
608 135th of 2000 higher than 1,865 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI